Subject within sequence effects [General Sta­tis­tics]

posted by Dr Andrew Leary – Ireland, 2012-05-02 19:48 (5157 d 09:57 ago) – Posting: # 8492
Views: 8,891

Dear Helmut & Co. - Greetings from sunny Ireland! [I promise - it REALLY is sunny!] :-D

A regulatory authority has asked some questions about a BE study my client performed back in the 1990s. In particular, they have asked that: “From the ANOVA tables, influence of treatment, period and subjects (subjects within sequence & sequence) effects should be submitted and discussed by the applicant”.

This was a standard two-way crossover BE study (properly designed with an adequate washout). All that is available of the statistical analysis are the summary statistics and ANOVA tables. I have had a look at these and see that for all primary parameters, the P values for treatment, period and sequence are non-significant (>0.05). However, again for all primary parameters, the P values for subject (sequence) are highly significant.

Can you tell me what, if anything, this might mean? In fashioning your answer, please take into account that I am a physician and not a statistician (i.e. you will need to confine yourself to words of one or two syllables only!). ;-)

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
135 visitors (0 registered, 135 guests [including 26 identified bots]).
Forum time: 05:46 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5